AR111082A1 - Citrulina para el tratamiento de la crisis de células falciformes - Google Patents

Citrulina para el tratamiento de la crisis de células falciformes

Info

Publication number
AR111082A1
AR111082A1 ARP180100446A ARP180100446A AR111082A1 AR 111082 A1 AR111082 A1 AR 111082A1 AR P180100446 A ARP180100446 A AR P180100446A AR P180100446 A ARP180100446 A AR P180100446A AR 111082 A1 AR111082 A1 AR 111082A1
Authority
AR
Argentina
Prior art keywords
treatment
falciform
citruline
cell crisis
crisis
Prior art date
Application number
ARP180100446A
Other languages
English (en)
Original Assignee
Univ Vanderbilt
The Univ Of Mississippi Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt, The Univ Of Mississippi Medical Center filed Critical Univ Vanderbilt
Publication of AR111082A1 publication Critical patent/AR111082A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

Un método para la administración de citrulina para el tratamiento de la crisis de células falciformes y otras complicaciones de la anemia de células falciformes.
ARP180100446A 2017-02-27 2018-02-26 Citrulina para el tratamiento de la crisis de células falciformes AR111082A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762463931P 2017-02-27 2017-02-27

Publications (1)

Publication Number Publication Date
AR111082A1 true AR111082A1 (es) 2019-05-29

Family

ID=63254039

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100446A AR111082A1 (es) 2017-02-27 2018-02-26 Citrulina para el tratamiento de la crisis de células falciformes

Country Status (8)

Country Link
US (2) US11351135B2 (es)
EP (1) EP3558286A4 (es)
CN (1) CN110325183A (es)
AR (1) AR111082A1 (es)
BR (1) BR112019017378A2 (es)
IL (1) IL268930A (es)
WO (1) WO2018157137A1 (es)
ZA (1) ZA201905081B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
US11660282B2 (en) 2020-02-10 2023-05-30 Nicox Sa Method for treating vaso occlusive crises associated with sickle cell disease
US20230404956A1 (en) * 2022-06-21 2023-12-21 Asklepion Pharmaceuticals Llc Therapeutic window for citrulline therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874471A (en) * 1997-02-27 1999-02-23 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US6028107A (en) * 1997-02-27 2000-02-22 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US6346382B1 (en) * 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
PT2247297T (pt) * 2008-01-31 2019-04-24 Univ Vanderbilt Tratamento terapêutico para estados pulmonares
US8840950B2 (en) 2010-05-26 2014-09-23 Jacqueline M. Hibbert Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
US20120076859A1 (en) * 2010-09-23 2012-03-29 Activaero Gmbh Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases
KR102320547B1 (ko) * 2015-06-29 2021-11-01 반더빌트유니버시티 수술 동안의 시트룰린의 정맥내 투여

Also Published As

Publication number Publication date
CN110325183A (zh) 2019-10-11
BR112019017378A2 (pt) 2020-03-31
IL268930A (en) 2019-10-31
US20180289647A1 (en) 2018-10-11
EP3558286A1 (en) 2019-10-30
ZA201905081B (en) 2022-03-30
US11351135B2 (en) 2022-06-07
EP3558286A4 (en) 2020-09-02
US20220304966A1 (en) 2022-09-29
WO2018157137A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
DOP2017000280A (es) Formas administración sólidas de palbociclib
CR20180525A (es) Producción de ácido ribonucleico libre de células
ECSP13012393A (es) Un agente de sostén
CR20150626A (es) Anticuerpos frente a ácidos teicoicos de pared y conjugados
EP3273079A4 (en) Electromagnetically enabled active type dynamic gas bearing
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
AR111082A1 (es) Citrulina para el tratamiento de la crisis de células falciformes
PH12017501096A1 (en) Aqueous ophthalmic solution
EP3471178A4 (en) NEGATIVE ELECTRODE ACTIVE SUBSTANCE, MIXED NEGATIVE ELECTRODE ACTIVE SUBSTANCE MATERIAL AND METHOD FOR PRODUCING A NEGATIVE ELECTRODE ACTIVE SUBSTANCE
CR20170485A (es) Producción de ácido ribonucleico libre de células
CY1123408T1 (el) Φαρμακευτικες συνθεσεις και χρηση των αυτων
BR112017014414A2 (pt) formulação farmacêutica
EP3476806A4 (en) SOLUTION, METHOD FOR PRODUCING THE SAME AND METHOD FOR PRODUCING AN ACTIVE SUBSTANCE OF A SECONDARY BATTERY
CO2017001712A2 (es) Formulaciones de compuestos biológicos para instilación
UY34505A (es) ?composición agroquímica, su uso, un método para controlar pestes y un método para preparar dicha composición?.
EP3626970A4 (en) VACUUM PUMP, MAGNETIC BEARING DEVICE FOR USE WITH A VACUUM PUMP, AND ELECTRIC MAGNETS ARRANGED IN A RING
MX2017006712A (es) Inhibidor de produccion de metaloproteinasa de matriz.
CO2017007669A2 (es) Películas envolventes con opacidad aumentada
AR112901A1 (es) Preparación de formas de dosificación sólidas que comprenden anticuerpos por estratificación de solución / suspensión
BR112017002915A2 (pt) processo para manufaturar um dispositivo de uso médico customizável e dispositivo obtido pelo dito processo
CO2018012110A2 (es) Procedimiento para la preparación de cuerpos moldeados para la administración a animales
EP3109679A4 (en) Method for manufacturing oriented film, and method for manufacturing display body
MX2018001219A (es) Composicion farmaceutica con estabilidad de almacenamiento mejorada y metodo para prepararla.
MX2018001221A (es) Composicion farmaceutica con estabilidad de almacenamiento mejorada y metodo para prepararla.
GB2543709A (en) Pharmaceutical agent